Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 16/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.45 |
| ▸ | CDK2 | P24941 | 8/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 8/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13376779 | 0.91 | IKBKB (0.45) | MAPK1CCNA2CDK2MAPK3MKNK1 | |
| SCHEMBL13376740 | 0.91 | MAPK1 (0.47) | MAPK1CCNA2CDK2MAPK3MKNK1 | |
| SCHEMBL13376704 | 0.91 | MAPK1 (0.45) | MAPK1CCNA2CDK2MAPK3MKNK1 | |
| SCHEMBL13376710 | 0.90 | MAPK1 (0.45) | MAPK1CCNA2CDK2MAPK3MKNK1 | |
| SCHEMBL13376705 | 0.90 | MAPK13 (0.45) | MAPK1CCNA2CDK2MAPK3MKNK1 | |
| SCHEMBL13376613 | 0.90 | MAPK1 (0.45) | MAPK1CCNA2CDK2MAPK3MKNK1 | |
| SCHEMBL13376712 | 0.90 | MAPK1 (0.47) | MAPK1CCNA2CDK2MAPK3MKNK1 | |
| SCHEMBL13376719 | 0.90 | MKNK1 (0.56) | MAPK1CCNA2CDK2MAPK3MKNK1 | |
| SCHEMBL13376746 | 0.88 | MAPK1 (0.42) | MAPK1CCNA2CDK2MAPK3 | |
| SCHEMBL13376745 | 0.87 | MAPK1 (0.43) | MAPK1CCNA2CDK2MAPK3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700771-B2 | Heterocyclic compound which may be used as a medicine having p38 MAP kinase inhibitory activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MAPK1, CHUK, MAPK3 | MAPK1 1/4885CCNA2 547/4885CDK2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.